Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation, optimization, and expansion study of MRG006A in advanced solid tumors
CTR20242454Phase 2Active
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MRG006A in hepatocellular carcinoma (HCC), Pulmonary squamous cell carcinoma, Nonhematologic neoplasms, sponsored by Lepu Biopharma Co., Ltd.. Started Aug 2024; status: active.
02
Drugs
MRG006A
03
Conditions
hepatocellular carcinoma (HCC)Pulmonary squamous cell carcinomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20242454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242454.